Integrating Emerging Evidence Into the Managem... - CLL Support

CLL Support

22,455 members38,596 posts

Integrating Emerging Evidence Into the Management of CLL Patients; what leading CLL experts recommend in 4 case studies

AussieNeil profile image
AussieNeilAdministrator
1 Reply

In this downloadable slideset from a symposium conducted at the NCCN 10th Annual Congress: Hematologic Malignancies™, a group of expert faculty explore the current data and provide their recommendations for 4 CLL cases:

1: Managing Otherwise Healthy Patients with CLL

2: Treatment Considerations for a Frail Patient with CLL

3: Managing Treatment-Related Symptoms

4: An Elderly Patient with Relapsed CLL and Clonal Evolution

Co-Chairs:

William G. Wierda, MD, PhD

Andrew D. Zelenetz, MD, PhD

Faculty:

Jacqueline Barrientos, MD

Jennifer R. Brown, MD, PhD

Steven E. Coutre, MD

Thomas J. Kipps, MD

The slideset includes consideration of the following treatments plus comparative Progression Free Survival (PFS) and Overall Survival (OS) for many of the new therapies as monotherapies and with mAbs from a range of clinical trials including CLL8 (FCR vs FC), CLL10 (FCR vs BR), CLL11 (Obinutuzumab), PROLONG (Ofatumumab Maintenance vs Obsereved in Relapsed CLL) and RESONATE-17 (Single-agent ibrutinib in del17p CLL/SLL).

Treatment options covered include:

Bendamustine and Rituximab (BR)

Chlorambucil + CD20 monoclonal Antibody (mAb)

Chlorambucil ± Ofatumumab

Fludarabine, Cyclophosphamide, and Rituximab (FCR)

Ibrutinib (BTK inhibitor)

Idelalisib (PI3K inhibitor) and Rituximab

Lenalidomide

Obinutuzumab and Chlorambucil

Rituximab and Chlorambucil

Venetoclax (Second Generation BCL-2 inhibitor)

Venetoclax + Rituximab

and of course.. Watch and Wait

Patients taking Idelalisib will be most interested in the information on the typical onset times of self-limiting and severe diarrhoea/colitis and how it may be controlled with Budesonide (slides 70 - 72) and transanimase elevations - liver function ALT or AST elevations (slides 73 - 75), Pneumonitis (slide 77).

The slideset (100 slides) is available from ClinicalOptions (free registration)

clinicaloptions.com/Oncolog...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Cllcanada profile image
CllcanadaTop Poster CURE Hero

I had some trouble with this on iDevices... the file is in Powerpoint .ppt, and not many things will open it... why they didn't also convert it to .pdf, I will never know...

There is a solution... go to the Apple App store and down load the free Microsoft app called ...wait for it...'Powerpoint' ...

Once that has installed you can open the slides in this app and it works fine... select 'Open in....' you will see the Powerpoint orange icon, select that and you are good to go...

~chris

You may also like...

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

clinical trials included in the evaluation were FCR vs FC, FCR vs BR and obinutuzumab in...

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

investigators found that patients who received obinutuzumab plus venetoclax had significantly higher

News about V+O and Acalabrutinib from EHA

Hi, The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs....

How things have changed

alternatives of FCR, monoclonal antibodies, -all the ...mab treatments - BTK inhibitors,...

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

ence-report-cll-btk-inhibitors-update? Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana